AMLX logo

AMYLYX PHARMACEUTICALS INC

AMLXNASDAQ
🏆 #1624 by market capEarnings Nov 4US Equity
$286.36▼ $4.81 (−1.68%)
Simulated price
🔔
Track AMLX
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 1.7%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$3.32B
Small Cap
📈Revenue Growth (YoY)
-100.0%
Declining
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
36
Weak
No chart data available for AMLX.

Trading Snapshot

Day Range
$284.80 – $289.44
52-Week Range
$10.83 – $41.14
Volume
$3.84B
Avg Volume
$2.60B
Shares Outstanding
111.2M
Next Earnings
Nov 16, 2026

Fundamentals Snapshot

Annual Revenue
$474M
Last Q Revenue
$130M
P/E Ratio
-21.2
P/S Ratio
0.0x
EPS (TTM)
$-1.37
Dividend Yield
0.00%
Dilution (1yr)
+37.9%

Why Investors Own AMLX

  • ✓High-growth profile — revenue up -0.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 28% gross margin and 12% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

AMLX logo

AMYLYX PHARMACEUTICALS INC

AMLX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▼ −100.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
51.8%▼ −44.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$153M▼ −51.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$123M▼ −26.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
94.6M▲ +37.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$221M▲ +$145M YoY
StockOtter · stockotter.space

About AMYLYX PHARMACEUTICALS INC

Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
36/100

Analyst Ratings

ⓘ
Consensus
Buy
18 analysts
Strong Buy9
Buy7
Hold2
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
CNBC·2h ago

AMYLYX PHARMACEUTICALS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift AMLX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

AMYLYX PHARMACEUTICALS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.